ADC THERAPEUTICS SA (ADCT) competitors & alternatives
Health Care · NYSE
ADC THERAPEUTICS SA (ADCT)'s top competitors and alternatives — its most similar public companies — include Gilead Sciences (GILD), ASTRAZENECA PLC (AZN), CYTOMX THERAPEUTICS INC (CTMX), KURA ONCOLOGY INC (KURA), AURA BIOSCIENCES INC (AURA), VERASTEM INC (VSTM), WHITEHAWK THERAPEUTICS INC (WHWK), Exelixis (EXEL), NURIX THERAPEUTICS INC (NRIX), OMNIAB INC (OABI), PERSPECTIVE THERAPEUTICS INC (CATX) and ORIC PHARMACEUTICALS INC (ORIC). These are ADC THERAPEUTICS SA's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top ADCT competitors & alternatives
-
Gilead SciencesGILDHealth Care
A diversified biopharmaceutical company pioneering viral disease treatments, cell therapies, and oncology medicines with a portfolio spanning HIV, hepatitis,…
$130.34 (as of 2026-07-22) · market cap $163.6B
-
ASTRAZENECA PLCAZN
Leading global biopharmaceutical company developing targeted oncology, cardiovascular, and rare disease treatments backed by a strong R&D pipeline.
$169.73 (as of 2026-07-22) · market cap $193.7B
-
CYTOMX THERAPEUTICS INCCTMXHealth Care
CytomX is developing conditionally activated cancer therapies using its PROBODY platform to enable selective tumor targeting with reduced systemic toxicity,…
$3.33 (as of 2026-07-22) · market cap $724M
-
KURA ONCOLOGY INCKURAHealth Care
Clinical-stage oncology company commercializing KOMZIFTI for cancer and advancing a pipeline of targeted therapeutics through strategic partnerships.
$10.54 (as of 2026-07-22) · market cap $944M
-
AURA BIOSCIENCES INCAURAHealth Care
Aura Biosciences is a clinical-stage biotech developing precision Viral-like Drug Conjugate (VDC) therapies designed to treat solid tumors while preserving…
$7.01 (as of 2026-07-22) · market cap $725M
-
VERASTEM INCVSTMHealth Care
A biopharmaceutical company developing targeted therapies for RAS/MAPK pathway-driven cancers, with a newly FDA-approved combination treatment for KRAS-mutated…
$5.89 (as of 2026-07-22) · market cap $527M
-
WHITEHAWK THERAPEUTICS INCWHWKHealth Care
Clinical-stage oncology company developing next-generation antibody-drug conjugates (ADCs) targeting validated tumor antigens with advanced linker-payload…
$3.99 (as of 2026-07-22) · market cap $216M
-
ExelixisEXELHealth Care
Exelixis is a profitable oncology company commercializing the multi-kinase inhibitor cabozantinib across multiple cancer indications while advancing a pipeline…
$54.98 (as of 2026-07-22) · market cap $14.0B
-
NURIX THERAPEUTICS INCNRIXHealth Care
Clinical-stage biotech pioneering AI-powered targeted protein degradation medicines for cancer and autoimmune diseases, with Phase 2 lead candidate…
$23.60 (as of 2026-07-22) · market cap $2.4B
-
OMNIAB INCOABIHealth Care
OmniAb provides a proprietary, AI-enhanced transgenic animal platform that accelerates the discovery of human antibody therapeutics for global pharmaceutical…
$2.11 (as of 2026-07-22) · market cap $300M
-
PERSPECTIVE THERAPEUTICS INCCATXHealth Care
Perspective Therapeutics is a clinical-stage oncology company pioneering targeted alpha therapy (TAT) to treat cancer through a proprietary radiopharmaceutical…
$2.97 (as of 2026-07-22) · market cap $337M
-
ORIC PHARMACEUTICALS INCORICHealth Care
ORIC Pharmaceuticals is a clinical-stage oncology company developing targeted therapies for hard-to-treat cancers through precision medicine approaches.
$10.75 (as of 2026-07-22) · market cap $1.1B
Not quite? Describe exactly what you want →
Peers are ADC THERAPEUTICS SA's closest public companies by shared sub-industry, sector and business themes. See the full profile: ADC THERAPEUTICS SA (ADCT).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.